Market Size Projection for Osteoporosis Diet and Nutrition (2024-2030)

The projected growth of the Osteoporosis Diet and Nutrition Market indicates an increase from USD 730.10 Million in 2023 to approximately USD 980.33 Million by 2030, reflecting a robust Compound Annual Growth Rate (CAGR) of 4.3% from 2024 to 2030. This expansion is primarily attributed to the escalating prevalence of Osteoporosis patients worldwide.

Overview of the Osteoporosis Diet and Nutrition Market

Osteoporosis manifests as a reduction in bone density and quality, predisposing individuals to fractures, notably in areas such as the wrist, hip, and spine. Multiple factors contribute to osteoporosis, encompassing genetic predispositions, inadequate intake of essential nutrients like calcium, magnesium, and vitamin D, as well as lifestyle factors including anorexia, sedentary behavior, excessive alcohol consumption, and certain medical conditions such as cancer, chronic kidney diseases, chronic obstructive pulmonary disease, and autoimmune disorders like rheumatoid arthritis.

Recent investigations have indicated potential bone-boosting benefits associated with the consumption of olive oil, soybeans, blueberries, and foods rich in omega-3 fatty acids, such as fish oil and flaxseed oil. While further research is warranted to establish conclusive links between these dietary elements and bone health, their recognized overall health benefits advocate for their inclusion in one's diet. Additionally, moderate consumption of specific alcoholic and non-alcoholic beverages like wine, beer, and tea has been associated with potential benefits for bone health, although further research is necessary to comprehensively understand this relationship.

Osteoporosis is characterized by porous bones, rendering them fragile and susceptible to fractures, often due to the overproduction of the hormone parathyroid. Additionally, the condition can arise from various diseases or treatments, including anorexia, alcoholism, kidney disease, hyperthyroidism, and surgical removal of ovaries. Certain medications exacerbate bone loss rates, including some anti-seizure drugs, proton pump inhibitors, chemotherapy agents, selective serotonin reuptake inhibitors, and glucocorticosteroids.

Impact of COVID-19 on the Osteoporosis Diet and Nutrition Market

The COVID-19 pandemic significantly impacted global markets, including the beverage sector. The laminate market, in particular, experienced substantial disruptions. Originating in late December in the Hubei province of Wuhan, China, COVID-19 rapidly spread worldwide, leading to widespread illness and economic repercussions. Governments, research institutions, and biotech and pharmaceutical companies have mobilized efforts towards rapid COVID-19 diagnosis technologies. Automotive production suffered disruptions, resulting in substantial losses across the sector. For example, passenger car registrations in the European Union plummeted by 53.4% in the second quarter of 2020. Consequently, demand for neopentyl glycol decreased significantly, impacting market growth in various regions.

Market Drivers:

The escalating prevalence of Osteoporosis patients is a significant driver of market growth.

Projected increases in osteoporosis incidence and prevalence during the forecast period are expected to propel market expansion. According to the INTERNATIONAL OSTEOPOROSIS FOUNDATION, osteoporosis leads to a fracture every 3 seconds globally, totaling more than 8.9 million fractures annually.

Market Restraints:

The high cost associated with osteoporosis diets and dietary supplements poses a restraint to market growth.

Although proper nutrition can address approximately 80% of bone weakening cases, the affordability of necessary dietary items throughout the treatment period may be prohibitive for many patients, thus constraining market growth.

Osteoporosis Diet and Nutrition Market - By Gender:

• Male
• Female
• Others

In terms of revenue, the female segment held a significant market share, likely due to an increase in osteoporosis incidence following menopause. A report by the International Osteoporosis Foundation indicates that nearly 30% of postmenopausal women worldwide suffer from osteoporosis due to low bone mass among 200 million individuals.

Furthermore, lifestyle factors such as alcohol consumption, sedentary habits, and smoking are found to exacerbate osteoporosis in women more than in men, according to the National Institutes of Health Osteoporosis and Related Bone Diseases. This heightened medical urgency to address osteoporosis is expected to drive the sales of osteoporosis drugs, leading to increased consumption rates over the forecast period of 2023-2028.

Osteoporosis Diet and Nutrition Market - By Region:

• North America
• Europe
• Asia-Pacific
• Latin America
• The Middle East
• Africa

North America dominated the Osteoporosis Diet and Nutrition Market with a 37% share in 2022. The region's high prevalence of osteoporosis patients, well-established healthcare infrastructure, availability of branded medications, and presence of key players continue to bolster its market. Substantial initial investments in research and development, along with increasing healthcare expenditure and supportive government initiatives, are expected to fuel market growth through 2030.

Europe is projected to follow North America in osteoporosis treatment, driven by new drug launches, government support, and other factors. For example, the European Commission's approval of EVENITY (romosozumab) for severe osteoporosis treatment in women highlights governmental efforts to raise awareness and expand the market. Additionally, the incidence of osteoporosis in France and Germany underscores the growing demand for osteoporosis treatment in Europe.

The Asia-Pacific market is poised to exhibit the highest CAGR, propelled by a growing elderly population with osteoporosis, increased adoption of new drugs, and robust healthcare expenditure, particularly in countries like China and India.

The Latin America and Middle East & Africa regions are in early stages of market development due to improving healthcare infrastructure and rising awareness among the population.

Osteoporosis Diet and Nutrition Market Share by Company:

1. Merck & Co. Inc.
2. Radius Health Inc.
3. Novartis AG
4. Eli Lilly and Company
5. Pfizer Inc.
6. Amgen Inc.
7. Novo Nordisk A/S
8. F. Hoffmann-La Roche Ltd.
9. UCB S.A.
10. Teva Pharmaceutical Industries Ltd.

Market players are employing various strategies, including mergers, acquisitions, joint ventures, partnerships, product innovations, research and development, and geographical expansions, to strengthen their positions in the industry. Dr. Reddy’s Laboratory recently launched Raloxifene, an osteoporosis drug in the U.S., aiming to expand treatment options and gain a competitive edge. The market is characterized by fragmentation, with vendors focusing on enhancing product offerings and providing efficient payment solutions to large enterprises.

RECENT DEVELOPMENTS IN THE INTERNATIONAL OSTEOPOROSIS DIET AND NUTRITION MARKET:

Product Introduction - During May 2021, Theramex, a pharmaceutical firm based in London, unveiled Livogiva, a medication for osteoporosis, within the European market.